Literature DB >> 1691012

Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group.

C Sessa1, W ten Bokkel Huinink, G Stoter, J Renard, F Cavalli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1691012     DOI： 10.1016/0277-5379(90)90295-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  7 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 2.  DNA hypomethylation in cancer cells.

Authors:  Melanie Ehrlich
Journal:  Epigenomics       Date:  2009-12       Impact factor: 4.778

3.  Decitabine in the treatment of myelodysplastic syndromes.

Authors:  Hussain I Saba
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

4.  Decitabine: a historical review of the development of an epigenetic drug.

Authors:  Dick de Vos; Wendy van Overveld
Journal:  Ann Hematol       Date:  2005-12       Impact factor: 3.673

Review 5.  Application of microRNA in diagnosis and treatment of ovarian cancer.

Authors:  Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kanako Nakamura; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Hiroyuki Nomura; Fumio Kataoka; Eiichiro Tominaga; Daisuke Aoki
Journal:  Biomed Res Int       Date:  2014-04-15       Impact factor: 3.411

Review 6.  Demethylating Agents in the Treatment of Cancer.

Authors:  Paul M Howell; Zixing Liu; Hung T Khong
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-02

7.  Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.

Authors:  Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths
Journal:  Epigenetics       Date:  2015       Impact factor: 4.861
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.